Abstract: Enzyme inhibition has become a cornerstone of modern therapeutics, targeting key molecular pathways implicated in cancer, metabolic disorders, and infectious diseases. This review explores diverse strategies of enzyme inhibition from classical active site-directed inhibitors to innovative biofilm-targeting enzymatic cocktails, emphasising their clinical utility. Beyond medicine, enzyme inhibitors are routinely employed to modulate nitrogen fixation, methanogenesis, and microbial dynamics in industrial and environmental settings. However, this dual-edged sword reveals its paradox: the very agent that heals can also harm. Their ecological persistence and bioaccumulation risks disrupt microbial ecosystems, foster antibiotic resistance, and affect non-target organisms. This review navigates the fine line between pharmaco-logical promise and environmental peril, evaluating risk assessment frameworks, mitigation strategies, and forward-looking approaches such as high-throughput screening, machine learning, and enzyme engineering. Ultimately, it advocates for a symbiotic integration of pharmaceutical innovation and environmental stewardship to create eco-friendly strategies that can enhance therapeutic efficacy without compromising ecological balance.
Building similarity graph...
Analyzing shared references across papers
Loading...
Mallamma T.
Jeevan Gowda
Rumaan M.
Current Drug Metabolism
Rajiv Gandhi University of Health Sciences
Ibn Sina National College for Medical Studies
Building similarity graph...
Analyzing shared references across papers
Loading...
T. et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69e71423cb99343efc98d8a6 — DOI: https://doi.org/10.2174/0113892002420090251206171649